291 related articles for article (PubMed ID: 34532333)
1. Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
Liu C; Fu Z; Jiang J; Chi K; Geng X; Mao Z; Song C; Sun G; Hong Q; Cai G; Chen X; Sun X
Front Med (Lausanne); 2021; 8():724456. PubMed ID: 34532333
[No Abstract] [Full Text] [Related]
2. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
[No Abstract] [Full Text] [Related]
3. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
4. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.
Chong S; Xie Q; Ma T; Xiang Q; Zhou Y; Cui Y
Front Pharmacol; 2022; 13():967532. PubMed ID: 36188528
[No Abstract] [Full Text] [Related]
5. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
[No Abstract] [Full Text] [Related]
7. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Jia L; Dong X; Yang J; Jia R; Zhang H
Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q
Front Pharmacol; 2022; 13():746265. PubMed ID: 35359863
[No Abstract] [Full Text] [Related]
9. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
11. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
13. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
15. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
Zhang L; Hou J; Li J; Su SS; Xue S
Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.
Abdelazeem B; Abbas KS; Shehata J; El-Shahat NA; Baral N; Savarapu P; Kunadi A
Ann Transl Med; 2021 Dec; 9(23):1714. PubMed ID: 35071408
[TBL] [Abstract][Full Text] [Related]
19. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
20. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
Mata Lorenzo M; Ali M; Mealing S; Moss J
J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
